|
Gene: ADAM23 |
Gene summary for ADAM23 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ADAM23 | Gene ID | 8745 |
Gene name | ADAM metallopeptidase domain 23 | |
Gene Alias | MDC-3 | |
Cytomap | 2q33.3 | |
Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | A0A024R3W8 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
8745 | ADAM23 | LZE4T | Human | Esophagus | ESCC | 5.19e-16 | 4.61e-01 | 0.0811 |
8745 | ADAM23 | LZE7T | Human | Esophagus | ESCC | 2.41e-03 | 2.71e-01 | 0.0667 |
8745 | ADAM23 | LZE21T | Human | Esophagus | ESCC | 1.12e-03 | 3.31e-01 | 0.0655 |
8745 | ADAM23 | P2T-E | Human | Esophagus | ESCC | 1.41e-13 | 3.25e-01 | 0.1177 |
8745 | ADAM23 | P4T-E | Human | Esophagus | ESCC | 3.03e-23 | 6.55e-01 | 0.1323 |
8745 | ADAM23 | P9T-E | Human | Esophagus | ESCC | 1.64e-08 | 2.71e-01 | 0.1131 |
8745 | ADAM23 | P11T-E | Human | Esophagus | ESCC | 1.08e-04 | 2.53e-01 | 0.1426 |
8745 | ADAM23 | P12T-E | Human | Esophagus | ESCC | 1.11e-04 | 2.00e-01 | 0.1122 |
8745 | ADAM23 | P15T-E | Human | Esophagus | ESCC | 1.63e-25 | 7.32e-01 | 0.1149 |
8745 | ADAM23 | P22T-E | Human | Esophagus | ESCC | 4.44e-15 | 2.78e-01 | 0.1236 |
8745 | ADAM23 | P26T-E | Human | Esophagus | ESCC | 1.21e-15 | 4.15e-01 | 0.1276 |
8745 | ADAM23 | P27T-E | Human | Esophagus | ESCC | 1.49e-07 | 1.97e-01 | 0.1055 |
8745 | ADAM23 | P30T-E | Human | Esophagus | ESCC | 4.22e-34 | 1.11e+00 | 0.137 |
8745 | ADAM23 | P31T-E | Human | Esophagus | ESCC | 1.25e-02 | 8.61e-02 | 0.1251 |
8745 | ADAM23 | P32T-E | Human | Esophagus | ESCC | 1.18e-10 | 2.80e-01 | 0.1666 |
8745 | ADAM23 | P37T-E | Human | Esophagus | ESCC | 3.28e-02 | 1.36e-01 | 0.1371 |
8745 | ADAM23 | P39T-E | Human | Esophagus | ESCC | 4.74e-07 | 1.28e-01 | 0.0894 |
8745 | ADAM23 | P40T-E | Human | Esophagus | ESCC | 7.95e-18 | 6.10e-01 | 0.109 |
8745 | ADAM23 | P42T-E | Human | Esophagus | ESCC | 1.24e-03 | 3.07e-01 | 0.1175 |
8745 | ADAM23 | P48T-E | Human | Esophagus | ESCC | 1.42e-17 | 6.42e-01 | 0.0959 |
Page: 1 2 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:199082316 | Esophagus | ESCC | response to leukemia inhibitory factor | 60/8552 | 95/18723 | 4.41e-04 | 2.48e-03 | 60 |
GO:199083015 | Esophagus | ESCC | cellular response to leukemia inhibitory factor | 59/8552 | 94/18723 | 6.19e-04 | 3.32e-03 | 59 |
GO:19908237 | Oral cavity | OSCC | response to leukemia inhibitory factor | 58/7305 | 95/18723 | 1.10e-05 | 1.14e-04 | 58 |
GO:19908307 | Oral cavity | OSCC | cellular response to leukemia inhibitory factor | 57/7305 | 94/18723 | 1.75e-05 | 1.71e-04 | 57 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ADAM23 | SNV | Missense_Mutation | c.1703A>T | p.Asp568Val | p.D568V | O75077 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-97-A4M7-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
ADAM23 | SNV | Missense_Mutation | c.218N>T | p.Pro73Leu | p.P73L | O75077 | protein_coding | tolerated_low_confidence(0.32) | benign(0) | TCGA-99-8025-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | gemzar | SD | |
ADAM23 | SNV | Missense_Mutation | c.2081N>T | p.Gly694Val | p.G694V | O75077 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-L9-A7SV-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | CR | |
ADAM23 | SNV | Missense_Mutation | c.2252G>T | p.Cys751Phe | p.C751F | O75077 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-21-1070-01 | Lung | lung squamous cell carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
ADAM23 | SNV | Missense_Mutation | novel | c.1187N>G | p.Tyr396Cys | p.Y396C | O75077 | protein_coding | deleterious(0.05) | possibly_damaging(0.852) | TCGA-21-A5DI-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
ADAM23 | SNV | Missense_Mutation | novel | c.2225G>T | p.Gly742Val | p.G742V | O75077 | protein_coding | deleterious(0.01) | possibly_damaging(0.89) | TCGA-22-0944-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ADAM23 | SNV | Missense_Mutation | novel | c.1370N>T | p.Gly457Val | p.G457V | O75077 | protein_coding | tolerated(0.51) | benign(0.065) | TCGA-34-2609-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | gemcitabine | PD |
ADAM23 | SNV | Missense_Mutation | c.739N>A | p.His247Asn | p.H247N | O75077 | protein_coding | deleterious(0) | possibly_damaging(0.809) | TCGA-34-5928-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ADAM23 | SNV | Missense_Mutation | novel | c.1793G>T | p.Arg598Leu | p.R598L | O75077 | protein_coding | deleterious(0.05) | possibly_damaging(0.68) | TCGA-56-7731-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ADAM23 | SNV | Missense_Mutation | novel | c.1953C>A | p.Ser651Arg | p.S651R | O75077 | protein_coding | deleterious(0.01) | possibly_damaging(0.589) | TCGA-56-8082-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |